PCSK9 inhibitors in combination with statins and ezetimibe are recommended for diabetic patients at high risk for cardiovascular disease who are on the maximum tolerated dose of statins and ezetimibe, with plasma LDL-C levels remaining above target [72] [+, I, A]. This evidence concerns the gene PCSK9 and cardiovascular disorder.